Literature DB >> 3282224

Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells.

V Cavailles1, P Augereau, M Garcia, H Rochefort.   

Abstract

The estrogen-induced 52K protein secreted by human breast cancer cells is a lysosomal protease recently identified as a pro-cathepsin D by sequencing several cDNA clones isolated from MCF7 cells (Augereau et al., Mol. Endocr.). Using one of these clones, we detected, in MCF7 cells, a 2.2 kb mRNA whose level was rapidly increased 4- to 10-fold by estradiol, but not by other classes of steroids. Other mitogens, such as epidermal growth factor and insulin, also induced the 2.2 kb mRNA in a dose-dependent manner. Induction with epidermal growth factor was as rapid but was 2- to 3-fold lower than with estradiol. Antiestrogens had no effect on the 52K-cathepsin-D mRNA in MCF7 cells, but became estrogen agonists in two antiestrogen-resistant sublines R27 and LY2. The use of transcription and translation inhibitors and nuclear run-on experiments indicate that estradiol enhances transcription of the 52K-cathepsin-D gene in MCF7 cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282224      PMCID: PMC338189          DOI: 10.1093/nar/16.5.1903

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  29 in total

1.  A human cell line from a pleural effusion derived from a breast carcinoma.

Authors:  H D Soule; J Vazguez; A Long; S Albert; M Brennan
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

2.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line.

Authors:  P Masiakowski; R Breathnach; J Bloch; F Gannon; A Krust; P Chambon
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

3.  Estrogen regulation of specific messinger RNA's in human breast cancer cells.

Authors:  D J Adams; D P Edwards; W L McGuire
Journal:  Biochem Biophys Res Commun       Date:  1980-12-31       Impact factor: 3.575

4.  Autocrine secretion and malignant transformation of cells.

Authors:  M B Sporn; G J Todaro
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

5.  A secreted glycoprotein induced by estrogen in human breast cancer cell lines.

Authors:  B Westley; H Rochefort
Journal:  Cell       Date:  1980-06       Impact factor: 41.582

6.  Immunohistochemical distribution of the 52-kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness.

Authors:  M Garcia; M J Lacombe; H Duplay; V Cavailles; D Derocq; J C Delarue; B Krebs; G Contesso; H Sancho-Garnier; G Richer
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

7.  Hormone responsive human breast cancer in long-term tissue culture: effect of insulin.

Authors:  C K Osborne; G Bolan; M E Monaco; M E Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

8.  Progestin increases cathepsin D synthesis in uterine luminal epithelial cells.

Authors:  B C Moulton; B B Koenig
Journal:  Am J Physiol       Date:  1983-05

9.  Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells.

Authors:  H Nawata; D Bronzert; M E Lippman
Journal:  J Biol Chem       Date:  1981-05-25       Impact factor: 5.157

10.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06
View more
  25 in total

1.  Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen.

Authors:  P E Budtz
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

2.  2,3,7,8-Tetrachlorodibenzo-p-dioxin causes an extensive alteration of 17 beta-estradiol metabolism in MCF-7 breast tumor cells.

Authors:  D C Spink; D W Lincoln; H W Dickerman; J F Gierthy
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 3.  Chromatin immunoprecipitation: advancing analysis of nuclear hormone signaling.

Authors:  Aurimas Vinckevicius; Debabrata Chakravarti
Journal:  J Mol Endocrinol       Date:  2012-09-05       Impact factor: 5.098

Review 4.  Cathepsin D in breast cancer.

Authors:  H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1990-07       Impact factor: 4.872

5.  Western blotting and isoform analysis of cathepsin D from normal and malignant human breast cell lines.

Authors:  L D Laury-Kleintop; E C Coronel; M K Lange; T Tachovsky; S Longo; S Tucker; J A Alhadeff
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

6.  Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer.

Authors:  W Remmele; J Sauer-Manthey
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells.

Authors:  Barbara C Spink; James A Bennett; Brian T Pentecost; Nicole Lostritto; Neal A Englert; Geoffrey K Benn; Angela K Goodenough; Robert J Turesky; David C Spink
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-18       Impact factor: 4.219

8.  Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells.

Authors:  V Krishnan; W Porter; M Santostefano; X Wang; S Safe
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

Review 9.  Evaluation of cathepsin D as a prognostic factor in breast cancer.

Authors:  P M Ravdin
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 10.  William L. McGuire Memorial Symposium. Control of breast cancer cell growth by steroids and growth factors: interactions and mechanisms.

Authors:  G Freiss; C Prébois; F Vignon
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.